FDA Grants Expanded Access to Experimental Pancreatic Cancer Drug
The Food and Drug Administration (FDA) has granted expanded access to an experimental pancreatic cancer drug, daraxonrasib, developed by Revolution Medicines. This decision allows a broader group of patients to receive the drug while it is still under regulatory review. The FDA's action underscores the urgent need for effective treatments for pancreatic cancer, one of the deadliest forms of cancer. Daraxonrasib has shown promise in clinical trials, doubling the average survival time for patients who have already undergone conventional treatment. The expanded access program, also known as compassionate use, will provide the drug at no cost to eligible patients, although insurance typically does not cover such drugs before approval. 
